<DOC>
	<DOC>NCT00824161</DOC>
	<brief_summary>The purpose of this study is to evaluate progression free survival primarily. The secondary objectives are to evaluate the antitumor activity, as assessed by objective tumor response, duration of clinical benefit, overall survival, and the safety profile of TAS-109</brief_summary>
	<brief_title>Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histologically confirmed colorectal adenocarcinoma Received prior therapy, at least two regimens, containing a fluoropyrimidine, oxaliplatin, and irinotecan Have at least one measurable tumor, as defined by RECIST Must be capable of maintaining a central venous line access Had previous antitumor therapy in the 3 weeks prior to study entry Have not recovered from all toxicities (excluding alopecia) from prior therapy to baseline or â‰¤grade 1 prior to study entry Have another malignancy in the past 3 years except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>